SpyGlass Pharma Unveils Compelling 1-Year Data of Its Innovative Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucoma   Share Mean intraocular pressure (IOP) reduction from washed-out baseline was 44.6% at Month 12; all patients had IOP reduction >20% and IOP ≤ 18 mmHg. 100% of patients remained off topical...

SpyGlass Pharma Strengthens Leadership to Further Advance its Intraocular Drug Delivery Platform Margot Goodkin, M.D., Ph.D., appointed Chief Medical OfficerBilal Khan, MBA, CEO of New World Medical, appointed to the SpyGlass Board of Directors ALISO VIEJO, Calif., Dec. 05, 2023 (GLOBE...

SpyGlass Pharma Initiates Phase I/II Clinical Trial of its Intraocular Drug Delivery Platform ALISO VIEJO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today the initiation of a Phase I/II clinical trial...

SpyGlass Pharma Unveils 6-Month Data from the First-In-Human Trial of Its Innovative Drug Delivery Platform for Chronic Eye Conditions ALISO VIEJO, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a privately held ophthalmic therapeutics company, released 6-month data from a First-in-Human glaucoma treatment trial showing...

SpyGlass Pharma Presents Compelling 3-Month Data from the First-In-Human Trial of Its Innovative Drug Delivery Platform for Chronic Eye Conditions ALISO VIEJO, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a privately held ophthalmic therapeutics company, today announced 3-month data from a First-in-Human glaucoma treatment trial...